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ABSTRACT
Background and aim: Modern treatment strategies for inflammatory bowel disease (IBD) are postu-
lated to change the natural disease course. Inception cohort studies are the gold standard for investi-
gating such changes. We have initiated a new population-based inception cohort study; Inflammatory
bowel disease in South Eastern Norway III (IBSEN III). In this article, we describe the study protocol
and baseline characteristics of the cohort.
Methods: IBSEN III is an ongoing, population-based observational inception cohort study with pro-
spective follow-up. Adult and pediatric patients with suspected IBD in the South-Eastern Health
Region of Norway (catchment area of 2.95 million inhabitants in 2017), during the 3-year period from
2017 to 2019, were eligible for inclusion. Comprehensive clinical, biochemical, endoscopic, demo-
graphic, and patient-reported data were collected at the time of diagnosis and throughout standar-
dized follow-up. For a portion of the patients, extensive biological material was biobanked.
Results: The study included 2168 patients, of whom 1779 were diagnosed with IBD (Crohn’s disease:
626, ulcerative colitis: 1082, IBD unclassified: 71). In 124 patients, there were subtle findings indicative
of, but not diagnostic for, IBD. The remaining 265 patients were classified as symptomatic non-
IBD controls.
Conclusion: We have included patients in a comprehensive population-based IBD cohort from a
catchment population of 2.95 million, and a unique biobank with materials from newly diagnosed and
treatment-naïve IBD patients and symptomatic non-IBD controls. We believe this cohort will add
important knowledge about IBD in the years to come.
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Introduction
In the early nineties, the Inflammatory Bowel disease in
South Eastern Norway (IBSEN) study reported the highest
incidence of inflammatory bowel disease (IBD) worldwide [1].
The IBSEN cohort, which was considered to be a ‘gold stand-
ard’ of population-based inception cohorts at the time, has
been followed for more than 20 years and contributed with
important data about the natural disease course of IBD [2–7].
However, the study included patients in the pre-biological
era and new medications as well as more stringent treatment
goals applied today are hypothesized to change the disease
course [8].
The current disease classification of Crohn’s disease (CD)
and ulcerative colitis (UC) has also been challenged, e.g. as
large genotype association studies have indicated that IBD is
better classified as a continuum of diseases [9]. New biomo-
lecular mapping of IBD patients combined with comprehen-
sive data on clinical disease course may unravel new disease
classifications focusing on disease outcome rather than anat-
omy. Further, a main challenge in IBD care today is the lack
of tools to predict disease course, which could aid individual-
ized treatment and care [10].
To investigate the possible impact of modern IBD man-
agement on disease course, study the rapid changes in epi-
demiology, and explore new and promising diagnostic and
prognostic factors that can be the basis of future precision
medicine in IBD, we have initiated a new population-based
IBD cohort study; Inflammatory Bowel Disease in South-
Eastern Norway III (IBSEN III). Within this cohort study we
have included a control group of symptomatic patients with-
out pathological findings. The study protocol and cohort’s
baseline characteristics are presented here.
Methods
Design and study population
IBSEN III is a population-based observational inception cohort
with prospective follow-up (Clinical Trials ID: NCT02727959).
Newly diagnosed IBD patients and symptomatic non-IBD
controls in the South-Eastern Health Region of Norway were
included during the 3-year period from 2017 to 2019.The
South-Eastern Health Region is the largest health region in
Norway, constituting a catchment area of approximately 2.95
million inhabitants (56% of the Norwegian population) in
2017 (Figure 1). Based on the latest IBD incidence data in
Norway [11] (assumed minimum incidence), and recently
published incidence data from Sweden [12] and Finland [13]
(assumed maximum incidence) we anticipated 531–876 eli-
gible patients with CD and 1134–2196 eligible patients with
UC. This would yield an estimated cohort of 1665–3072
newly diagnosed IBD patients.
Setting
In Norway, there is free access to healthcare for all inhabi-
tants. Patients with symptoms contact their general practi-
tioner and are referred to the secondary health service when
needed. All pediatric IBD patients and the large majority of
adult IBD patients are diagnosed and receive their first treat-
ment at public hospitals. There are a few private gastroenter-
ology centers, e.g. eight in the South-Eastern Health Region
in the inclusion period.
Inclusion process
All general practitioners and the private gastroenterology
centers in the South-Eastern Health Region were informed of
the ongoing study by letter and invited to refer all patients
with symptoms and clinical findings suspicious of IBD to
their local hospital. Individuals with suspected IBD based on
referral letters were invited to participate in the study.
Patients who fulfilled internationally accepted diagnostic cri-
teria (Lennard-Jones criteria for adults [14], revised Porto cri-
teria for children [15]) after initial diagnostic work-up were
included as definite IBD cases. Patients with subtle findings
indicative of IBD [on endoscopy or magnetic resonance
imaging (MRI)], but who did not meet full diagnostic criteria,
were also included and classified as ‘suspicion of small bowel
IBD’ or ‘suspicion of large bowel IBD’. Patients with symp-
toms of IBD, but without endoscopic or histologic signs of
inflammation, were classified as ‘symptomatic non-IBD con-
trols’. These patients remained in the study as a control
group. Exclusion criteria were other causes of acute or
chronic bowel inflammation, i.e. infectious colitis, radiation
colitis, diversion colitis, solitary rectal ulcer syndrome, graft
versus host disease, diverticular colitis, medication associated
colitis, ischemic colitis, microscopic colitis, and enema associ-
ated colitis.
Data collection and biobanking
The IBSEN III study design included two modules (Table 1).
All hospitals performed Module 1, which included compre-
hensive clinical, endoscopic, demographic, and patient-
reported data, as well as fecal samples for analyses of
Figure 1. The geographical areas of inclusion of patients to the population-
based inception cohort studies (a) IBSEN, recruited from the counties of Oslo,
Østfold, Telemark and Aust-Agder during 1990–1994, and (b) IBSEN III, recruited
from the counties of Agder (previously Aust-Agder and Vest-Agder), Innlandet
(previously Oppland and Hedmark), Oslo, Vestfold and Telemark, and Viken
(previously Buskerud, Akershus and Østfold), corresponding to the South-
Eastern Health Region of Norway, during 2017–2019.
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calprotectin and microbiota, before start of treatment. At the
first ileocolonoscopy, biopsies were collected from six prede-
termined bowel segments (ileum, colon ascendens, transver-
sum, descendens, sigmoideum and rectum) and additionally
from the coecum in pediatric cases. In patients with diag-
nosed or suspected CD, systematic recording of early small
bowel MRI was conducted. Analyses of routine blood sam-
ples and stool cultures were performed at the local laborato-
ries as part of routine follow-up and the results were
registered. The three largest hospitals in the region (Oslo
University Hospital, Akershus University Hospital and Vestfold
Hospital) also performed Module 2, which included extensive
additional biobanking and additional PROMs in both incident
IBD cases as well as symptomatic non-IBD controls. The col-
lected data were based on reports from the patients, evalua-
tions from the treating clinician, and information registered
in the electronic patient records. All data were entered dir-
ectly into an electronic clinical research form (CRF) system
(Viedoc#, PCG Solutions AB, Uppsala, Sweden), including an
internet-based system for patient-reported outcome meas-
ures (PROMs) (ViedocMe).
Prescheduled clinical follow-ups with the same systematic
and comprehensive registration of data are planned at 1 and
5 years after diagnosis. After 3 and 6 months, and after 3
years, patient-reported data and fecal samples are collected
(Table 1). The Standard Operation Procedures of IBSEN III (in
Norwegian) are added as Supplemental Material.
Definitions
Disease phenotype, location, and extent were evaluated
according to the Montreal classification [16] at time of diag-
nosis, and re-evaluated at each clinical follow-up. Change in
phenotype at 1-year follow-up was defined by the appear-
ance of newly affected segments or complications (stenosis
or fistula) after the initial diagnostic work-up. Disease relapse
was defined as symptoms of IBD that led to changes in the
treatment. Numbers of relapses were registered and ‘chronic
symptoms without remission’ during the observed periods
were also registered. Local complications were defined as
stenosis, fistula and/or abscess. Number of hospital admis-
sions and total number of admitted days due to IBD were
registered. Surgeries were registered as numbers of events,
type of surgery (appendectomy, colectomy, segmental resec-
tion of colon, small bowel resection, perianal drainage of
abscess, perianal fistula surgery), and for colectomy, its indi-
cation (acute severe colitis, refractory colitis, dysplasia/can-
cer). IBD-relevant medication (including elemental diet) was
registered with the relevant drug and number of months
during which the drug was used. The reason for stopping a
biological drug was registered as ‘development of antibod-
ies’, ‘side effects’, ‘non-response without antibodies’, or
‘other’. Curves visually illustrating disease course were also
adapted from the IBSEN study [2].
Registries
The unique personal identification number of Norwegian citi-
zens provides the opportunity to link the clinical cohort to
several nationwide health registries and population-based
health studies. Linkage to the Norwegian Patient Registry will
enable evaluation of completeness of the cohort and
increase data quality. Linkage to other health registries will
also be performed in substudies of IBSEN III investigating
topics such as mortality, cancer risk, and socioeconomic
impact (Table 2).














Clinical interview x x x
Clinical examination Xa xa xa
Endoscopy including biopsies xb xb,c,d xb,c,d
Blood samples x x x
Fecal samplese x x x x x x
MRI small bowel (CD) x xc xc
Module 2 extensive biobanking
Blood x x x
Intestinal biopsies x x x
Urine x x x
Oropharyngeal swabs x x
PROM
Adult patients
SF-36 x x x x x x
IBDQ x x x x x x
EQ 5D 5L x x x x x x
FQ x x x x
MARS x x x x
GSE x x x x
HADS x x x x x x
FSS x x x x x x
BPI x x x
PSQI x x x
Rome IV x x x x
FFQ x x x x
Pediatric patients
KIDSCREENf x x x x x x
GSEg x x x x
FSSg x x x x x x
HADSg x x
BPIg x x x x x x
Module 2 PROM
Adult patients
BPI x x x x x x
PSQI x x x x x x
MSAS x x x x
aClinical examination for assessment of disease activity with validated activity
indices (Harvey Bradshaw Index and Simple Clinical Colitis Activity Index),
complications, extra intestinal manifestations, comorbidity and treatment.
Clinical phenotype according to Montreal classification.
bVideo recordings of endoscopies at module 2 centers.
cIf clinical indication.
d±3months.
eFecal samples (tube without preservatives and PSPVR Spin Stool DNA sam-
pling tube) for biobanking and analysis of f-calprotectin.
fFrom 8 years.
gFrom 12 years.
BPI: Brief Pain Inventory; CD: Crohn’s disease; EQ 5D: 5 L,5-level version of the
EQ 5 D; FQ: Fatigue Questionnaire; FSS: Fatigue Severity Scale; FFQ: Food
Frequency Questionnaire; GSE: General Self-Efficacy Scale; HADS: Hospital
Anxiety and Depression Scale; IBDQ: Inflammatory Bowel Disease
Questionnaire; MARS: Medication Adherence Rating Scale; MSAS: Memorial
Symptom Assessment Scale; PROM: patient reported outcome measures; PSQI:
Pittsburgh Sleep Quality Index; SF-36: Short Form 36.
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Statistics
Continuous data are presented as median with ranges, cat-
egorical data as counts and percentages. Statistical analyses
were performed using IBM SPSS Statistics for Windows, ver-
sion 24 (Armonk, NY).
Ethical considerations
The IBSEN III study was approved by the South-East Regional
Committee for Medical and Health Research Ethics (Ref 2015/
946-3). All patients signed an informed consent form before
participating in the study. For patients younger than 18 years,
parents/legal guardians signed the informed consent form.
Patients 16 or 17 years of age co-signed together with their
parents/legal guardians.
Results
A total of 2168 patients were included in the study. A flow
chart of included patients is presented in Figure 2. A total of
1779 patients were diagnosed with IBD: 626 patients with
CD, 1082 patients with UC and 71 patients with IBD unclassi-
fied. In 124 patients, there were subtle findings indicative of,
but not diagnostic for, IBD: 76 suspicious of small bowel IBD
and 48 suspicious of large bowel IBD. The remaining 265
patients were classified as symptomatic non-IBD controls.
The inclusion rate was stable at approximately 63 patients
per month (Figure 3). Only one of the hospitals (catchment
area of approximately 83 000 in 2017, 2.8% of the South-
Eastern Health Region) failed to include any patients.
During the study period, 373 patients with newly diag-
nosed or suspected IBD did not consent (i.e. were not asked
or declined) to inclusion in the IBSEN III study. Due to ethical
regulations, we were not allowed to collect any further infor-
mation on this group of patients.
Baseline characteristics of the patients included in the
cohort are shown in Table 3. In Table 4, we present an over-
view of biological material collected from baseline in the
IBSEN III biobank subgroup (Module 2), including the number
of fecal samples collected from the entire cohort at baseline.
Discussion
We present a new population-based inception cohort of IBD
patients, the IBSEN III cohort. This large-scale, unselected and
treatment-naïve study population is optimal for studies of
IBD disease course in the biological era as well as prognos-
tic studies.
In the nineties, the original IBSEN study was considered
to represent the ‘gold standard’ of population-based
cohorts. Since then many large-scale, well-characterized
cohorts have been developed, all with their strengths and
limitations [17–20]. The IBSEN III study has many advan-
tages compared to other IBD cohorts. Norway has a stable,
traceable population combined with a public health care
system. This allows for inclusion of a large cohort of newly
diagnosed and treatment naïve patients from a well-
defined geographical area. The population-based design of
the IBSEN III study, including both adult and pediatric
cases, increases the potential generalizability of the study
results. Based on previous studies of incidence in similar
Table 2. Overview of National registries and databases to be linked with the IBSEN III study.
National registry
Data for linkage with participants
in the IBSEN III study Planned analyses
The Norwegian Patient Registry Diagnostic and therapeutic activities in the
specialist health care services
Epidemiological verification of the completeness of
the cohort
Evaluation of health care use by IBD patients
compared to the general population
The Norwegian Prescription Database Prescribed IBD-related medications including
medication suspected to influence risk of IBD or
gut microbiota
Verify completeness of data in electronic CRF and
avoid recollection bias
The Norwegian Cause of Death Registry Date and cause of death Evaluation of mortality and causes of death
compared to the general population
Norwegian Cancer Registry Date and diagnoses of cancer Evaluation of cancer-specific morbidity compared
to the general population
Registry for social security benefits Social security benefits including sick leave and
work disability
Evaluation of direct and indirect costs of IBD
Database for refunds pursuant to the National
Insurance Act
Refunds for treatment in primary and specialist
health care services
Evaluation of direct and indirect costs of IBD
Registry for nursing and cares services Registered received nursing and care services Evaluation of direct and indirect costs of IBD
Norwegian Mother, Father and Child Cohort Study Data regarding diet in childhood Investigations of environmental risk factors
Figure 2. Flow chart of patients included in the study. Diagnosis of inflamma-
tory bowel disease was set based on Lennard-Jones criteria for adults [14] and
Porto criteria for children [15].
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Nordic populations and countries, we estimated 531–876
eligible patients with CD and 1134–2196 eligible patients
with UC, resulting in a predicted cohort of 1665–3072 after
three years’ inclusion. The cohort size of 1779 newly diag-
nosed IBD patients, and additionally the 373 patients, who
did not consent to inclusion, indicates that the cohort size
is within the lower range of this estimate. To assess the
completeness of the cohort, we will link data from the
Norwegian Patient Registry and compare the number of
incident patients in this registry within the corresponding
geographical area and inclusion years, with the number of
included patients. Validation of correct diagnoses in the
Norwegian Patient Registry has been performed with other
diagnoses [21], but not within IBD. However, a Swedish
study found high validity of IBD diagnoses within the
Swedish Patient Registry [22].
Figure 3. Number of included patients during the study period, from each center and total inclusion rate.










N 626 1082 71 76 48 265 86
Age—median years (range) 31.5 (3–81) 34.0 (3–84) 30.0 (4–65) 34.5 (2–81) 31.0 (5–73) 27.0 (1–74) 27.5 (3–68)
Female gender. % of n 52.1 45.8 49.3 59.2 45.8 50.6 50
Current smoking yes. % of na 11.9 5.6 9.8 12.8 7.4 19.6 14.7
Level of education. % of nb
9 years 9.8 10.1 2.4 17.4 11.1 8.6 11.8
10–12 years 45.5 41.2 48.8 39.1 48.1 41.7 35.3
>12 years 44.7 48.7 48.8 43.5 40.7 49.7 52.9
Time with symptoms. median months (range) 8.5 (0–576) 4.0 (0–240) 5.0 (0–132) 9.0 (0–396) 6.0 (0–600) 12.0 (0–240) 6.0 (0–132)
Age groups. % of n
Pediatric IBD <18 years 18.8 7.2 28.2 17.1 16.7 17 43
Adult IBD 18–65 years 75.9 87.2 71.8 72.4 77 81.5 55.8
Geriatric IBD >65 years 5.3 6.6 0 10.5 6.3 1.5 1.2
CD: Crohn’s disease; IBD-U: inflammatory bowel disease unclassified; susp: suspicion of; IBD: inflammatory bowel disease; UC: ulcerative colitis.
aSmoking: patients >18 years (n¼ 1935), missing ¼ 466.
bLevel of education: patients >18 (n¼ 1935), missing ¼ 467.
Table 4. Overview of collected biobank material at baseline.
IBD Suspected IBD Symptomatic non-IBD control
Blood (serum, plasma, whole blood, Paxgene) 623 59 252
Intestinal biopsies 403 51 236
Urine 512 51 220
Fecal samples (all centers) 1218 85 183
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The first IBSEN study generated important data on IBD’s
natural disease course [2,3], prognostic factors for disease
course [4–6], and risk of cancer and mortality [7]. However,
the IBSEN study included patients diagnosed in the pre-bio-
logical era (early nineties) and the introduction of biologics is
postulated to change the disease course of IBD. The IBSEN III
cohort is recruited from the same geographical area and fol-
lowed with the same study design and corresponding or
improved methods as the first IBSEN study. This will generate
comparable data from both cohorts in general, and will also
allow for analyses of the possible disease-modifying effects
of biologics and immunomodulators on disease course.
The era of multi-omics proposes a future treatment strat-
egy based on diagnostic, prognostic and predictive models
[23]. The IBSEN III cohort is thoroughly characterized, both
clinically and biochemically. We expect that results from fur-
ther biomolecular mapping of the cohort can identify diag-
nostic markers and possibly a new biomolecular-based
disease classification, as well as predictors of dis-
ease outcome.
We have included a symptomatic non-IBD control group
in the present study. We will also continue to follow patients
with possible IBD but with subtle findings that did not meet
the diagnostic criteria. Prospective follow-up including re-
evaluation of the diagnosis will provide the opportunity to
study diagnostic and prognostic markers in these patients.
Limitations
To include all newly diagnosed IBD patients in the region
was challenging and selection bias cannot be excluded. We
are aware of almost 400 patients that were considered for
inclusion but not invited or declined inclusion. The final diag-
nosis of these patients is not known to us. The sensitivity of
the inclusion will be evaluated by comparison of IBD cases in
the Norwegian Patient Registry as described above. Also, the
study was designed with ‘other causes of acute or chronic
bowel inflammation’ as an exclusion criterion, and we only
kept the symptomatic patients without any findings in our
control group. As one of our aims is to increase diagnostic
precision, this might turn out to be a limitation in fur-
ther studies.
The study is investigator-initiated, was designed with lim-
ited resources, and relies on the efforts of many healthcare
workers in 19 hospitals. Implementation had to be adapted
to local procedures. Three-month and six-month follow-ups
are therefore not performed as clinical visits. The patients
received text messages that reminded them to answer ques-
tionnaires and deliver fecal samples. This approach may have
led to reduced response rates at the 3- and 6-month fol-
low-ups.
Due to differences in disease severity at onset, some
patients were unable to deliver fecal samples, and in some
cases other biological material as well, before start of treat-
ment. Therefore, not all of the biobanked material is col-
lected from treatment-naïve patients. Still, the quantity of
biological material from purely treatment-naïve patients is
substantial and will generate important future study results.
The IBSEN III study has also been affected by the COVID-
19 pandemic. In the period from March to June 2020, most
of the scheduled 1-year follow-up visits had to be postponed
or cancelled. We find it likely that the most severe cases
were prioritized for clinical follow-up during this period, thus
this might have introduced bias. Luckily, this was only rele-
vant for a minor group of patients included in 2019, and as
of autumn 2020 1-year follow-ups seem to be running nor-
mally again.
Conclusion
With limited resources, we have built a comprehensive popu-
lation-based cohort from a catchment population of 2.95 mil-
lion, and a unique biobank with materials from newly
diagnosed and treatment-naïve IBD patients and symptom-
atic non-IBD controls. This cohort will increase knowledge
about IBD in the years to come.
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